Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

The Lancet

Volumn 388, Issue 10048, 2016, Pages 963-973

  Singh, Dave ^a   Papi, Alberto ^b   Corradi, Massimo ^c   Pavlišová, Ilona ^d   Montagna, Isabella ^e   Francisco, Catherine ^f   Cohuet, Géraldine ^f   Vezzoli, Stefano ^e   Scuri, Mario ^e   Vestbo, Jørgen ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d Odborny Plicni Lekar   (Czech Republic)

^e CHIESI FARMACEUTICI S P A   (Italy)

^f Laboratoire Chiesi   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METERED DOSE INHALER; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; OPEN STUDY; PARALLEL DESIGN; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; VIRAL RESPIRATORY TRACT INFECTION; XEROSTOMIA; AGED; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECTS; DYSPNEA; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84989195861     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31354-X     Document Type: Article

References (30)

1. 1 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org, 2016 (accessed July 22, 2016).
2. 2 Abudagga, A, Sun, SX, Tan, H, Solem, CT, Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis. Int J Chron Obstruct Pulmon Dis 8 (2013), 175–185.
3. 3 Müllerová, H, Shukla, A, Hawkins, A, Quint, J, Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open, 4, 2014, e006171.
4. 4 Solem, CT, Sun, SX, Sudharshan, L, Macahilig, C, Katyal, M, Gao, X, Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 8 (2013), 641–652.
5. 5 Celli, BR, Thomas, NE, Anderson, JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008), 332–338.
6. 6 Donaldson, GC, Seemungal, TAR, Bhowmik, A, Wedzicha, JA, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002), 847–852.
7. 7 Johannesdottir, SA, Christiansen, CF, Johansen, MB, et al. Hospitalization with acute exacerbation of chronic obstructive pulmonary disease and associated health resource utilization: a population-based Danish cohort study. J Med Econ 16 (2013), 897–906.
8. 8 Calverley, PMA, Anderson, JA, Celli, B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
9. 9 Tashkin, DP, Celli, B, Senn, S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008), 1543–1554.
10. 10 Brusselle, G, Price, D, Gruffydd-Jones, K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 10 (2015), 2207–2217.
11. 11 Aaron, SD, Vandemheen, KL, Fergusson, D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146 (2007), 545–555.
12. 12 Cazzola, M, Andò, F, Santus, P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 20 (2007), 556–561.
13. 13 Frith, PA, Thompson, PJ, Ratnavadivel, R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial. Thorax 70 (2015), 519–527.
14. 14 Hoshino, M, Ohtawa, J, Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration 86 (2013), 280–287.
15. 15 Jung, KS, Park, HY, Park, SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 106 (2012), 382–389.
16. 16 Singh, D, Brooks, J, Hagan, G, Cahn, A, O'Connor, BJ, Superiority of ‘triple’ therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63 (2008), 592–598.
17. 17 Jones, PW, Beeh, KM, Chapman, KR, Decramer, M, Mahler, DA, Wedzicha, JA, Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 189 (2014), 250–255.
18. 18 European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) (EMA/CHMP/483572/2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf, 2012 (accessed Aug 11, 2016).
19. 19 Leidy, NK, Murray, LT, Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD 10 (2013), 393–398.
20. 20 Hanania, NA, Crater, GD, Morris, AN, Emmett, AH, O'Dell, DM, Niewoehner, DE, Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 106 (2012), 91–101.
21. 21 Welte, T, Miravitlles, M, Hernandez, P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 (2009), 741–750.
22. 22 Siler, TM, Kerwin, E, Sousa, AR, Donald, A, Ali, R, Church, A, Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med 109 (2015), 1155–1163.
23. 23 US Department of Health and Human Services. Chronic obstructive pulmonary disease: developing drugs for treatment—guidance for industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071575.pdf, 2016 (accessed Aug 11, 2016).
24. 24 Wedzicha, JA, Decramer, M, Ficker, JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1 (2013), 199–209.
25. 25 Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
26. 26 Short, PM, Williamson, PA, Elder, DHJ, Lipworth, SIW, Schembri, S, Lipworth, BJ, The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 141 (2012), 81–86.
27. 27 Bateman, ED, Ferguson, GT, Barnes, N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 42 (2013), 1484–1494.
28. 28 Singh, D, Jones, PW, Bateman, ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med, 14, 2014, 178.
29. 29 Kew, KM, Seniukovich, A, Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, 2014 CD010115.
30. 30 Singh, D, Corradi, M, Spinola, M, Petruzzelli, S, Papi, A, Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med, 26, 2016, 16030.